RANTES (CCL5) regulates airway responsiveness after repeated allergen challenge

Toshiyuki Koya, Katsuyuki Takeda, Taku Kodama, Nobuaki Miyahara, Shigeki Matsubara, Annette Balhorn, Anthony Joetham, Azzedine Dakhama, Erwin W. Gelfand

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

RANTES (CC chemokine ligand 5) contributes to airway inflammation through accumulation of eosinophils, but the exact role of RANTES (CCLS) is not defined. C57BL/6 mice, sensitized by injection of ovalbumin (OVA) on Days 1 and 14, were challenged with OVA on Days 28, 29, and 30 (3 challenges, short-term-challenge model) or on Days 28, 29, 30, 36, 40, 44, and 48 (7 challenges, repeated-challenge model) and evaluated 48 h later. Anti-mouse RANTES was given intravenously, and recombinant mouse RANTES or PBS was given intratracheally. These reagents were given on Days 28, 29, and 30 in the short-term-challenge study and on Days 44 and 48 in the repeated-challenge study. After short-term challenge, there were no effects after administration of anti-RANTES or RANTES. In the repeated-challenge study, although control mice showed a decrease in airway hyperresponsiveness, administration of anti-RANTES sustained and enhanced airway hyperresponsiveness and increased goblet cell numbers. In contrast, administration of RANTES normalized airway function but reduced goblet cell numbers. IL-12 and IFN-γ levels in BAL decreased in the anti-RANTES group and increased in the RANTES group. IFN-γ-producing CD4 T cells in lung, and IFN-γ production from lung T cells in response to OVA in the anti-RANTES group, were significantly decreased but were increased in the RANTES group. Anti-IFN-γ, administered with RANTES, decreased the effects of RANTES on AHR after repeated challenge. These data indicate that RANTES plays a role in the regulation of airway function after repeated allergen challenge, in part through modulation of levels of IFN-γ and IL-12.

Original languageEnglish
Pages (from-to)147-154
Number of pages8
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume35
Issue number2
DOIs
Publication statusPublished - Aug 2006
Externally publishedYes

Fingerprint

Chemokine CCL5
Allergens
Ovalbumin
Goblet Cells
T-cells
Interleukin-12
Cell Count
T-Lymphocytes
Dimercaprol
CC Chemokines
Lung
Inbred C57BL Mouse
Eosinophils

Keywords

  • Airway hyperresponsiveness
  • IFN-γ
  • IL-12
  • RANTES (CCL5)

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Pulmonary and Respiratory Medicine

Cite this

RANTES (CCL5) regulates airway responsiveness after repeated allergen challenge. / Koya, Toshiyuki; Takeda, Katsuyuki; Kodama, Taku; Miyahara, Nobuaki; Matsubara, Shigeki; Balhorn, Annette; Joetham, Anthony; Dakhama, Azzedine; Gelfand, Erwin W.

In: American Journal of Respiratory Cell and Molecular Biology, Vol. 35, No. 2, 08.2006, p. 147-154.

Research output: Contribution to journalArticle

Koya, T, Takeda, K, Kodama, T, Miyahara, N, Matsubara, S, Balhorn, A, Joetham, A, Dakhama, A & Gelfand, EW 2006, 'RANTES (CCL5) regulates airway responsiveness after repeated allergen challenge', American Journal of Respiratory Cell and Molecular Biology, vol. 35, no. 2, pp. 147-154. https://doi.org/10.1165/rcmb.2005-0394OC
Koya, Toshiyuki ; Takeda, Katsuyuki ; Kodama, Taku ; Miyahara, Nobuaki ; Matsubara, Shigeki ; Balhorn, Annette ; Joetham, Anthony ; Dakhama, Azzedine ; Gelfand, Erwin W. / RANTES (CCL5) regulates airway responsiveness after repeated allergen challenge. In: American Journal of Respiratory Cell and Molecular Biology. 2006 ; Vol. 35, No. 2. pp. 147-154.
@article{7716e8f46dce486499aa6f193a75fb10,
title = "RANTES (CCL5) regulates airway responsiveness after repeated allergen challenge",
abstract = "RANTES (CC chemokine ligand 5) contributes to airway inflammation through accumulation of eosinophils, but the exact role of RANTES (CCLS) is not defined. C57BL/6 mice, sensitized by injection of ovalbumin (OVA) on Days 1 and 14, were challenged with OVA on Days 28, 29, and 30 (3 challenges, short-term-challenge model) or on Days 28, 29, 30, 36, 40, 44, and 48 (7 challenges, repeated-challenge model) and evaluated 48 h later. Anti-mouse RANTES was given intravenously, and recombinant mouse RANTES or PBS was given intratracheally. These reagents were given on Days 28, 29, and 30 in the short-term-challenge study and on Days 44 and 48 in the repeated-challenge study. After short-term challenge, there were no effects after administration of anti-RANTES or RANTES. In the repeated-challenge study, although control mice showed a decrease in airway hyperresponsiveness, administration of anti-RANTES sustained and enhanced airway hyperresponsiveness and increased goblet cell numbers. In contrast, administration of RANTES normalized airway function but reduced goblet cell numbers. IL-12 and IFN-γ levels in BAL decreased in the anti-RANTES group and increased in the RANTES group. IFN-γ-producing CD4 T cells in lung, and IFN-γ production from lung T cells in response to OVA in the anti-RANTES group, were significantly decreased but were increased in the RANTES group. Anti-IFN-γ, administered with RANTES, decreased the effects of RANTES on AHR after repeated challenge. These data indicate that RANTES plays a role in the regulation of airway function after repeated allergen challenge, in part through modulation of levels of IFN-γ and IL-12.",
keywords = "Airway hyperresponsiveness, IFN-γ, IL-12, RANTES (CCL5)",
author = "Toshiyuki Koya and Katsuyuki Takeda and Taku Kodama and Nobuaki Miyahara and Shigeki Matsubara and Annette Balhorn and Anthony Joetham and Azzedine Dakhama and Gelfand, {Erwin W.}",
year = "2006",
month = "8",
doi = "10.1165/rcmb.2005-0394OC",
language = "English",
volume = "35",
pages = "147--154",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "2",

}

TY - JOUR

T1 - RANTES (CCL5) regulates airway responsiveness after repeated allergen challenge

AU - Koya, Toshiyuki

AU - Takeda, Katsuyuki

AU - Kodama, Taku

AU - Miyahara, Nobuaki

AU - Matsubara, Shigeki

AU - Balhorn, Annette

AU - Joetham, Anthony

AU - Dakhama, Azzedine

AU - Gelfand, Erwin W.

PY - 2006/8

Y1 - 2006/8

N2 - RANTES (CC chemokine ligand 5) contributes to airway inflammation through accumulation of eosinophils, but the exact role of RANTES (CCLS) is not defined. C57BL/6 mice, sensitized by injection of ovalbumin (OVA) on Days 1 and 14, were challenged with OVA on Days 28, 29, and 30 (3 challenges, short-term-challenge model) or on Days 28, 29, 30, 36, 40, 44, and 48 (7 challenges, repeated-challenge model) and evaluated 48 h later. Anti-mouse RANTES was given intravenously, and recombinant mouse RANTES or PBS was given intratracheally. These reagents were given on Days 28, 29, and 30 in the short-term-challenge study and on Days 44 and 48 in the repeated-challenge study. After short-term challenge, there were no effects after administration of anti-RANTES or RANTES. In the repeated-challenge study, although control mice showed a decrease in airway hyperresponsiveness, administration of anti-RANTES sustained and enhanced airway hyperresponsiveness and increased goblet cell numbers. In contrast, administration of RANTES normalized airway function but reduced goblet cell numbers. IL-12 and IFN-γ levels in BAL decreased in the anti-RANTES group and increased in the RANTES group. IFN-γ-producing CD4 T cells in lung, and IFN-γ production from lung T cells in response to OVA in the anti-RANTES group, were significantly decreased but were increased in the RANTES group. Anti-IFN-γ, administered with RANTES, decreased the effects of RANTES on AHR after repeated challenge. These data indicate that RANTES plays a role in the regulation of airway function after repeated allergen challenge, in part through modulation of levels of IFN-γ and IL-12.

AB - RANTES (CC chemokine ligand 5) contributes to airway inflammation through accumulation of eosinophils, but the exact role of RANTES (CCLS) is not defined. C57BL/6 mice, sensitized by injection of ovalbumin (OVA) on Days 1 and 14, were challenged with OVA on Days 28, 29, and 30 (3 challenges, short-term-challenge model) or on Days 28, 29, 30, 36, 40, 44, and 48 (7 challenges, repeated-challenge model) and evaluated 48 h later. Anti-mouse RANTES was given intravenously, and recombinant mouse RANTES or PBS was given intratracheally. These reagents were given on Days 28, 29, and 30 in the short-term-challenge study and on Days 44 and 48 in the repeated-challenge study. After short-term challenge, there were no effects after administration of anti-RANTES or RANTES. In the repeated-challenge study, although control mice showed a decrease in airway hyperresponsiveness, administration of anti-RANTES sustained and enhanced airway hyperresponsiveness and increased goblet cell numbers. In contrast, administration of RANTES normalized airway function but reduced goblet cell numbers. IL-12 and IFN-γ levels in BAL decreased in the anti-RANTES group and increased in the RANTES group. IFN-γ-producing CD4 T cells in lung, and IFN-γ production from lung T cells in response to OVA in the anti-RANTES group, were significantly decreased but were increased in the RANTES group. Anti-IFN-γ, administered with RANTES, decreased the effects of RANTES on AHR after repeated challenge. These data indicate that RANTES plays a role in the regulation of airway function after repeated allergen challenge, in part through modulation of levels of IFN-γ and IL-12.

KW - Airway hyperresponsiveness

KW - IFN-γ

KW - IL-12

KW - RANTES (CCL5)

UR - http://www.scopus.com/inward/record.url?scp=33746787729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746787729&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2005-0394OC

DO - 10.1165/rcmb.2005-0394OC

M3 - Article

C2 - 16528011

AN - SCOPUS:33746787729

VL - 35

SP - 147

EP - 154

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 2

ER -